Lilly’s Mounjaro and Zepbound Reach $36.5B in 2025; CFO to Speak March 2
Eli Lilly’s Mounjaro and Zepbound injections generated $36.5 billion in combined sales in 2025, accounting for about 56% of the company’s total revenue and boosting its fourth-quarter results beyond expectations. CFO Lucas Montarce will discuss these drivers and outline the company’s 2026 outlook during a fireside chat at TD Cowen’s 46th Annual Health Care Conference on March 2 via live webcast.
1. GLP-1 Revenue Drivers
In 2025, Eli Lilly’s tirzepatide-based drugs Mounjaro for type II diabetes and Zepbound for obesity generated combined global sales of $36.5 billion, representing approximately 56% of total company revenue.
2. Bullish 2026 Outlook
Following strong fourth-quarter results led by GLP-1 momentum, Lilly issued a bullish financial outlook for 2026, expecting continued growth driven by expanding market share in diabetes and obesity care.
3. TD Cowen Conference Appearance
CFO Lucas Montarce will join a fireside chat at TD Cowen’s 46th Annual Health Care Conference on March 2 at 3:10 p.m. Eastern, with a live webcast available via Lilly’s investor website.